# Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma

> **NCT02352831** · PHASE1,PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 16 (actual)

## Conditions studied

- Pancreatic Cancer
- Cancer of Pancreas
- Cancer of the Pancreas
- Pancreas Cancer

## Interventions

- **DRUG:** Tosedostat
- **DRUG:** Capecitabine
- **PROCEDURE:** Fresh tissue biopsy

## Key facts

- **NCT ID:** NCT02352831
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-31
- **Primary completion:** 2017-10-20
- **Final completion:** 2018-10-19
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Insufficient funding and drug supply from manufacturer
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02352831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02352831, "Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02352831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*